The healthcare services industry has been witnessing a gradual process of internationalisation in the last couple of years and domestic hospital chains, diagnostic networks and specialty care providers have been expanding their operations beyond their home turf to tap into growth opportunities in the international market, as reimbursement pressures and competition have intensified in the Indian market.
Across Central Asia, South-east Asia and the Gulf, emerging markets are often a better place for those that have tested their operating model in their home markets to scale outwards, with lower competition and higher realisations per patient, particularly for companies specialising in chronic disease management like dialysis, oncology, cardiac care.
Shares of Nephrocare Health Services Ltd. were trading at Rs. 691.25, up 0.24 percent from previous close of Rs. 689.60. The stock opened at Rs. 695.00, reaching an intraday high of Rs. 695.00 and low of Rs. 677.60. The company currently has a market capitalization of Rs. 6,914 crores.
What’s the news?
On 1st September 2026, Nephrocare Health Services Limited (Nephrocare), the parent of India’s largest dialysis network under the NephroPlus brand, announced to the stock exchanges that it has entered into a Sale and Purchase Agreement with Dialysis Center Almaty LLP, a dialysis services provider incorporated in Kazakhstan, for acquiring 100% participatory interest in the latter. The overall negotiation value of the deal is KZT 561.66 million or about Rs. 11.6 crore, which can be reduced in accordance with the terms of the agreement, but the company stated that the transaction does not qualify as a related party.
The turnover of the target entity, incorporated in February 2019, with 34 dialysis machines at centres in Kazakhstan, in calendar year 2025 was KZT 527.44 million (about Rs. 10.9 crore), which rose by about 21% year-on-year from 2024 to 2025. Upon completion, subject to regulatory approvals from Kazakhstan, including state re-registration, the target will be an overseas step-down subsidiary of Nephrocare, providing Nephrocare with a second operating site in Kazakhstan.
Financial & Business Analysis
Looking at the quarterly results of Nephrocare Health Services Ltd., the company’s consolidated revenue from operations increased by 23.71 percent YoY, from Rs. 234.35 crore in Q1 FY26 to Rs. 289.92 crore in Q1 FY27, and increased by 4.60 percent QoQ from Rs. 277.18 crore in Q4 FY26.
In Q1 FY27 BEML Ltd., consolidated net profit increased by 34.89 percent YoY, reaching Rs. 31.97 crore compared to Rs. 23.70 crore during the same period last year. As compared to Q4 FY26, the net profit has increased by 5.27 percent, from Rs. 30.37 crore.
The basic earnings per share increased by 13.12 percent and stood at Rs. 3.19 as against Rs. 2.82 recorded in the same quarter in the previous year, FY2026.
The real value of this acquisition is what it adds to an international business that has already shifted the revenue mix for Nephrocare: international markets contributed just 12% of revenue in FY23 but jumped to nearly 42% in FY26, as the company expanded into higher-realisation geographies where treatment pricing and return on capital both exceed the domestic segment.
Consolidated FY26 revenue grew 32.2% YoY to Rs. 998.8 crore and adjusted EBITDA up 37.6% to Rs. 238.1 crore at a 23.8% margin and management has guided for 15-20% compounded revenue growth over the next three to four years, a target that relies heavily on this kind of bolt-on international expansion rather than domestic capacity addition alone.
Kazakhstan becomes the latest stop in a playbook Nephrocare has already run successfully elsewhere: the company entered the Philippines around six years ago with an acquisition of six clinics and has since scaled that footprint to 43 clinics, one of the country’s largest dialysis networks, while also building a presence in Uzbekistan and Saudi Arabia. Return on capital employed improved by 290 basis points to 22.8% in FY26, and with treatment volumes up 16.6% for the year across a base of captive, public-private-partnership and standalone facilities, each new overseas centre added through acquisition even a small one like Almaty – feeds directly into the higher-margin international mix that’s now doing most of the heavy lifting on growth.
Industry Overview
The rising global burden of diabetes and hypertension is also increasing the burden of CKD, and the global kidney dialysis market, which was valued at approximately USD 91 billion in 2025, is expected to reach approximately USD 134 billion by 2030 with a compound annual growth rate (CAGR) of approximately 8% and is projected to impact nearly 10% of the world’s population.
India’s dialysis market is growing faster than the rest of the world with uneven dialysis access outside metros from an estimated $12 billion in 2024 to expected to reach $24 billion by 2030 at a CAGR of over 10% which is the space organised chains such as NephroPlus have targeted to grow their network in India.
In fact, the emerging markets of Central Asia and Southeast Asia offer the same opportunity, but at a younger stage with less developed organised dialysis infrastructure, reimbursement programmes supported by the government, and fewer established private operators that have competed away small providers at affordable prices through the use of standardised clinical procedures.
Asia-Pacific is widely cited by industry researchers as the region with the highest growth rate for dialysis demand through 2030 and, as NephroPlus’s international business already appears to be in the lead over its business in India, small acquisitions of this sort can more easily be thought of as an entry point into a repeatable expansion model across an underpenetrated regional patient base.
Company Overview
Nephrocare Health Services Limited, trading as NephroPlus, is the largest dialysis network in Asia, with a diverse mix of captive clinics, public-private-partnership centers and standalone facilities across India and several international markets including the Philippines, Uzbekistan and Saudi Arabia, with headquarters in Hyderabad. The company, which was listed on the BSE and NSE in December 2025, has since focused on overseas expansion, largely through targeted acquisitions of local dialysis providers, as a key pillar of its growth strategy along with the continued deepening of its domestic network.